Clinical and cost-effectiveness of insulin degludec: from clinical trials to clinical practice.

about

A Large Difference in Dose Timing of Basal Insulin Introduces Risk of Hypoglycemia and Overweight: A Cross-Sectional Study

P2860

Q37737467-526B2205-869D-4DBB-9E02-0C31DC0F0644

P2860

Clinical and cost-effectiveness of insulin degludec: from clinical trials to clinical practice.

Item

http://www.wikidata.org/entity/Q38470334

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Clinical and cost-effectivenes ...... l trials to clinical practice.

@en

type

Item

label

Clinical and cost-effectivenes ...... l trials to clinical practice.

@en

prefLabel

Clinical and cost-effectivenes ...... l trials to clinical practice.

@en

P1476

Clinical and cost-effectivenes ...... l trials to clinical practice.

@en

P2093

Marc Evans

http://www.w3.org/2001/XMLSchema#string

Phil McEwan

http://www.w3.org/2001/XMLSchema#string

P2860

Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes

Ligand-controlled assembly of hexamers, dihexamers, and linear multihexamer structures by the engineered acylated insulin degludec

10-year follow-up of intensive glucose control in type 2 diabetes

Insulin degludec compared with insulin glargine in insulin-naïve patients with type 2 diabetes: A 26-week, randomized, controlled, Pan-Asian, treat-to-target trial.

Defining and characterizing the progression of type 2 diabetes.

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority tria

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority tria

Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN(®) Basal-Bolus Type 1): 2-year results of a randomized clinical

Insulin degludec versus insulin glargine in type 1 and type 2 diabetes mellitus: a meta-analysis of endpoints in phase 3a trials.

A comparison of health-related quality of life (health utility) between insulin degludec and insulin glargine: a meta-analysis of phase 3 trials.

P304

1-8

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/CER.15.10

http://www.w3.org/2001/XMLSchema#string

P577

2015-05-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25959645

http://www.w3.org/2001/XMLSchema#string

Clinical and cost-effectiveness of insulin degludec: from clinical trials to clinical practice.

about

P2860

P2860

Clinical and cost-effectiveness of insulin degludec: from clinical trials to clinical practice.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P577

P698